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A B S T R A C T
Parkinson’s disease (PD) is a major health problem worldwide affecting millions of people and is a result of
neurodegeneration in a small part of the brain known as substantia nigra pars compacta. Aberration in mi-
tochondrial Ca2+ homeostasis plays, among several other factors, an important role for the neuronal loss in PD.
Mitochondria are vital for cellular physiology, e.g. for ATP generation, and mitochondrial Ca2+ is a key player in
cell functioning and survival. Mitochondrial Ca2+ homeostasis is maintained by a fine balance between the
activities of proteins mediating the influx and efflux of Ca2+ across mitochondrial membranes. Malfunctioning
of these proteins leading to Ca2+ overload promotes ROS generation, which induces cell death by triggering the
opening of mitochondrial permeability transition pore. Till now PD remains incurable and the “gold standard”
drug which can only delays the disease progression is L-Dopa from the 1960s and therefore, the situation
warrants the search for novel targets for the treatment of the PD patients. In this review, we summarize the
current views that suggest mitochondrial Ca2+ regulatory pathways are good candidates for the treatment of PD.
1. Introduction
Neurological, mental, and behavioral diseases are common in all
countries and affect millions of people worldwide. Importantly, there
are no effective treatments for many of these disorders. To develop the
strategies and efficient drugs to stop them or at least to delay their
progress, more basic research is needed. Two major neurodegenerative
disorders are Alzheimer’s disease (AD) and Parkinson’s disease (PD)
affecting about 50 and 6 million people around the world, respectively.
These numbers will likely increase because of aging of the world’s po-
pulation. Age is a major risk factor in AD and PD, however, the en-
vironmental factors might also contribute to pathogenesis.
Major parts of the brain such as entorhinal cortex and hippocampus
are affected in AD, whereas PD results from neurodegeneration process
in a small and defined area of the brain called substantia nigra pars
compacta (SNpc). This region in the midbrain is involved in movement
control and contains dopaminergic neurons (DNs), which degenerate
during the progress of the disease. Dopaminergic cell loss is one of two
primary criteria for the diagnosis of PD [1]. The etiology of PD involves
multiple factors, including genetic and environmental ones. For
instance, a compound called 1-methyl-4-phenyl-1,2,3,6-tetra-
hydropyridine (MPTP) produces a rapid onset of parkinsonian syn-
drome associated with a degeneration of DNs. Some factors such as
caffeine or anti-inflammatory drugs may play a protective role by re-
ducing the risk of developing PD.
Mutations in six genes such as α-SNCA, ATP13A2, DJ-1, LRRK2,
Parkin, and PINK1 are known to cause the familial PD [2]. Remarkably,
in different PD versions there is an apparent intracellular Ca2+ dysre-
gulation, e.g. loss of function of PINK1 gene leads to Ca2+ mishandling
[3–6]. Considering that in neurons, many reactions are regulated by
Ca2+, it is understandable that Ca2+ signaling is fundamentally im-
portant for proper neuronal functions and survival [7]. Global changes
in Ca2+ homeostasis accompanied by the alteration in the bioenergetic
status and thereby imposing oxidative stress on the cells are reported in
PD [8,9]. For example, α-Synuclein, a 140-amino acid residues cyto-
solic protein involved in the pathogenesis of PD, was reported to form
α-helical channels in the plasma membrane and allow extracellular
Ca2+ transfer and thereby increases cytosolic Ca2+ concentration
[9,10]. Additionally, recent research revealed the presence of α-Synu-
clein in mitochondria as well as in mitochondria associated ER
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membrane [11,12]. Interestingly, Paillusson et al. demonstrated that α-
synuclein induced loosening of ER–mitochondria contacts disrupt Ca2+
exchange between these two organelles and thereby strongly affect PD
phenotype [13]. Likewise, an enhanced activity of L-type Ca2+ chan-
nels leading to increased cytosolic Ca2+ influx has been shown in PD
[14]. Enhanced cytosolic Ca2+ concentration, on the other hand, affects
the bioenergetics of the cells by promoting a higher ATP demand [9].
Moreover, this alteration in cytosolic Ca2+ hampers the normal Ca2+
handling by various intracellular organelles and thus threatens neu-
ronal viability [4–6,15]. Cytosolic Ca2+ is sequestered into different
cellular organelles such as endoplasmic reticulum, mitochondria, Golgi,
and lysosomes [16–20]. There are extensive evidences for the func-
tional involvement of mitochondria, in particular mitochondrial oxi-
dative stress, in PD [21,22]. Interestingly, inhibiting mitochondrial
Ca2+ uptake diminishes the oxidative stress in SNpc DNs indicating that
mitochondrial oxidative stress may also be the consequence of mi-
tochondrial Ca2+ overload and not only for the need of enhanced ATP
production [23].
Despite long-lasting efforts PD is still incurable. However, there are
treatments which can improve the quality of life of the patients. The use
of compound L-DOPA, a dopamine precursor which easily crosses
blood-brain barrier, as a treatment for PD was introduced in the sixties
and it still remains the pharmacological “gold standard” approach [24].
During recent years many therapies were evaluated to improve symp-
toms in PD. The list of these compounds includes rasagiline, amanta-
dine, pramipexole, ropinirole [24], and selegiline [25]. Isradipine, a
dihydropyridine Ca2+ channel antagonist (interacts with CaV1.2 and
CaV1.3 channels in the hippocampus) was shown to be neuroprotective
in in vitro and in vivo Parkinson models [26,27]. A phase III trial is going
on to evaluate the efficacy of isradipine to slow the progression of
disability in early PD [28]. Isradipine will be an attractive choice in the
PD treatment because this drug easily crosses the blood-brain barrier
and is already approved for the treatment of high blood pressure
[25,26]. This is an exciting development since in another clinical trial,
focused on related field of NMDA receptor-based stroke treatments
(glutamate-induced excitotoxicity) have failed due to many side effects
[29,30]. However, a lot of questions remain to be answered regarding
the beneficial effect and thus the use of isradipine in PD pathology. For
example, what is the mechanism responsible for the beneficial inhibi-
tion of the plasma membrane Ca2+ channels? Does isradipine treatment
reduces mitochondrial Ca2+ overload and thus acts as a neuroprotec-
tive agent? It has already been pointed out that mitochondrial and
neuronal dysfunction in PD is caused by mitochondrial calcium influx
[6]. This indicated that Pink1 has an important function in regulating
mitochondrial activity under stress conditions. Recent research from
our group support their observations and indicated that knocking out
Mcu, which leads to a blockade of Ca2+ entrance to the mitochondrial
matrix, rescues the loss of dopaminergic neurons in Pink1 mutant of
Danio rerio [31]. Therefore, in this review we are exploring whether it
would be possible to target mitochondrial Ca2+ regulatory components
in PD pathology. In the subsequent sections, we will first scrutinize the
role of the candidate proteins responsible for mitochondrial Ca2+
transport and then we will discuss mitochondrial Ca2+ flow pathways
as potential drug targets for PD therapy.
2. Calcium in mitochondria
Ca2+ inside the mitochondria regulates different processes that are
crucial for cell functioning. These ions are involved in energy produc-
tion (ATP), opening of the mitochondrial permeability transition pore
(mPTP) and both triggering and preventing apoptosis [32]. There are
several potential entry and exit sites for Ca2+ in mitochondria, and key
players were depicted on the Fig. 1. Ca2+ concentration in mitochon-
dria depends on the routes sprawling across ER, mitochondrion-asso-
ciated membranes (MAMs) and mitochondria [33,34].
Two major channels that mediate Ca2+ influx into mitochondria are
(i) Voltage dependent anion channel (VDAC) and (ii) the mitochondrial
calcium uniporter (MCU) [35–41]. VDAC is located in the outer mi-
tochondrial membrane (OMM) and is responsible for the transport of
Ca2+ to the inter-membrane space (IMS). Till now three different iso-
forms of VDAC have been identified, VDAC1, VDAC2 and VDAC3.
Among them VDAC1 has been best studied, whereas only a limited
information is available for VDAC2 or VDAC3 [42]. VDAC1, being
highly Ca2+-permeable, permits Ca2+ into and out of the mitochondria
thereby affecting various cellular processes [43–46]. Importantly,
VDAC1 functions in the junction between mitochondria and ER to fa-
cilitate the passage of Ca2+ from ER to mitochondria and regulate the
apoptotic cell death pathways [47,48].
Ca2+ movement from the IMS to the mitochondrial matrix is
mediated by MCU, which is located in the inner-mitochondrial mem-
brane (IMM) and have low Ca2+ affinity. Mitochondrial matrix Ca2+
([Ca2+]m) level is almost equal to that of cytoplasm (∼100 nM) under
resting conditions and therefore MCU is inactive despite the driving
force of the mitochondrial transmembrane potential (ΔΨ(m)), which is
produced by the respiratory chain. However, upon stimulation when
the cytoplasmic Ca2+ concentration ([Ca2+]c) rises rapidly (to
500–800 nM or even higher in some cells [49]), the MCU becomes
active and passes Ca2+ into mitochondria instantaneously [38,49–51].
The MCU activity is manipulated by its regulatory proteins [52], which
altogether form a heteromeric complex. The components of the MCU
heteromeric complex includes mitochondrial calcium uptake (MICU1,
MICU2 and MICU3), MCU dominant negative beta subunit (MCUb),
essential MCU regulator (EMRE), MCU regulator 1 (MCUR1) and
SLC25A23. Although MCU is expressed ubiquitously, the expression
patterns of its regulatory proteins are tissue specific [53]. An interesting
structure-function relationship exists between MCU and its regulators in
order to manipulate the activity of MCU [52]. MICU1 works as a vital
gatekeeper of MCU and inhibits its activity. Later on, it was found that
MICU2 interacts with MICU1 in its inhibitory, gatekeeper role to keep
the channel closed below a certain Ca2+ threshold [49]. MCUR1 and
MCUb directly bind to MCU exerting a positive and dominant negative
effect on MCU activity, respectively [51,54,55]. The other protein
EMRE is required for the interaction of MCU with MICU1 and MICU2
[56]. At low cytosolic Ca2+ level MICU2 inhibits MCU activity by
binding with MICU1. When cytosolic Ca2+ level increases MICU1-
MICU2 dimer dissociates from the heteromeric complex and therefore,
loses its inhibitory activity, and ultimately Ca2+ flows from cytosol into
mitochondria through MCU [52].
A recent article from our group showed that (a) mitochondria that
were isolated from mcu−/− zebrafish were unable to absorb Ca2+ from
the medium and (b) those fish were viable, fertile and lacked gross
Fig. 1. Possible Ca2+ transporters with proven or potential pharmacological
modulators for the treatment of Parkinson’s disease. For the modulators, only
one example is presented herein. For details consult Table 1.
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morphological aberrations [31]. A similar outcome was found in the
previous mice study by Pan et al. [57]. These observations support
earlier report by Marongiu et al. [6] that blockage of mitochondrial
calcium influx completely rescues mitochondria from damage induced
by mutant Pink1. Likewise, the knockout of Mcu in mice on a CD1
background was not lethal and had a weak phenotype, which suggests
the existence of additional entry routes to mitochondria [58]. If this
unrecognized entry route exists in mitochondria, it may require the
activity of channels or other proteins that reside in the ER and/or PM
[38,40]. One such pathway might involve rapid uptake mode (RaM)
[59], but its molecular identity has not yet been defined. Another
pathway might be mitochondrial ryanodine receptor (RyR) that is ex-
pressed at high levels in neurons [38,60] or channel that consists of
LETM1 (leucine zipper- EF- hand containing transmembrane protein 1)
[61–64]. LETM1 is a high affinity mitochondrial Ca2+/H+ exchanger
[61,63], and is able to drive both extrusion and uptake of Ca2+ into
energized mitochondria at submicromolar Ca2+ concentrations. LETM1
has been shown to maintain the mitochondrial tubular shape [65].
However, debates continue regarding its role in Ca2+ extrusion
[61,66].
There are still other candidates, which could be responsible for
Ca2+ influx inside the mitochondria, e.g. (i) UCP2 [67] and UCP3
(BMCP1), which are highly expressed in the brain [68], (iii) proteins
that belong to the family of TMBIM membrane proteins, such as TMBIM
(called also GHITM, MICS1, or DERP2) [69], (iv) potential channel
proteins that are listed in MitoCarta, but do not have an assigned
function [70].
Ca2+ efflux from the mitochondrial matrix to IMS is a necessity for
the cells in order to maintain resting Ca2+ level inside the mitochon-
dria. This efflux is mediated by a well-known mitochondrial Na+/Ca2+
exchanger, NCLX (encoded by the SLC8B1 gene) importing 3 Na+ in
exchange of 1 Ca2+ [4,71]. NCLX is different from plasma membrane
NCX with respect to its sensitivity towards Li+. A recent study from Roy
et al. provide functional insights into the unique selectivity for Li+ and
Na+ of the mitochondrial exchanger [71]. They identified distinct Na+
and Li+ selective residues in the NCLX transport site and propose that
functional segregation in Li+ and Na+ sites reflects the functional
properties of NCLX required for Ca2+ exchange under the unique
membrane potential and ion gradient across the inner mitochondrial
membrane.
Another mechanism for Ca2+ release from mitochondria is through
the transient opening of mPTP, the molecular composition of which is
yet undefined. It is proposed that mPTP is composed of several different
protein components such as VDAC1 (in the OMM), ANT (in the IMM),
F0F1-ATP synthase [38,72], and cyclophilin D in the matrix [73–75].
Nevertheless, its function is probably related to Ca2+ overload that
depolarizes mitochondria leading to activation of different cell path-
ways associated with pathophysiological conditions [74–76].
3. Mitochondrial Ca2+ pathways as targets of anti-PD treatment
It has been reviewed that crosstalk between different mitochondrial
proteins is involved in several physiological and pathophysiological
conditions [77]. Ca2+ uptake into the mitochondrial matrix helps to
maintain normal synaptic activity via enhanced respiratory function
[78,79]. However, enhanced or sustained Ca2+ stress results in mi-
tochondrial injury due to Ca2+ overload. Excess mitochondrial Ca2+
uptake or impaired Ca2+ efflux results in ROS production [80,81],
breakdown of membrane potential and opening of the mPTP, and
therefore induction of neuronal cell death, an important indicator of
several different neurological disorders including AD and PD. Our
group explored the mechanisms of early onset PD of genetic origin by
using zebrafish with mutation in pink1 gene, which exhibits loss of
about 20% of DNs already at 5 days post fertilization (dpf) [3,31].
Dysregulation of Ca2+ transport into mitochondria seems to be an early
molecular mechanism of the pathology [47,82–86]. We found that both
a morpholino against mcu and its pharmacological inhibition by Ru-
thenium Red rescued the loss of dopaminergic neurons in pink1−/−
zebrafish [3]. A subsequent study confirmed the role of Mcu in rescuing
the neuronal loss by using a double mutant zebrafish (pink1;mcu)−/ −
model [31]. This data shows that in Pink1-PD model the lack of Mcu
rescues the pathology. We also showed that the absence of Mcu made
the fish resistant to MPTP, a drug that kills dopaminergic neurons, and
often used to make models of PD [24]. Very recently, Marco et al. [87]
claimed that inhibition of MICU1 activity by two newly identified
pharmacological inhibitors namely MCU-i4 and MCU-i11 can prevent
mitochondrial Ca2+ overload. A similar outcome was observed in
LRRK2-PD model with increased intracellular Ca2+ uptake, which re-
sults in enhanced mitophagy and thus mitochondrial loss [88]. The
treatment with VDAC inhibitors rescued the neurons from mitophagic
death, again indicating the importance of Ca2+ uptake in controlling
the neuronal cell fate [88].
While different studies implicated MCU in the PD pathology, studies
of others suggested that pharmacological inhibition of NCLX with
CGP37157 was neuroprotective [5,89]. However, Ruiz et al. later
showed that the neuroprotective effect of CGP37157 is not only through
its inhibitory action on NCLX, but it also modulates cytosolic and mi-
tochondrial Ca2+ dynamics via VGCCs [90]. Nevertheless, the work
from Elrod group unravel the importance of NCLX in cell viability [81].
They demonstrated that animals with tamoxifen-induced deletion of
NCLX gene died within several hours after gene deletion, which was
associated with mitochondrial Ca2+ overload and induction of the
mPTP pore. Alongside with this report, research from two different
laboratories, by using PINK1 and LRRK2 PD models, provided evi-
dences which demonstrated that NCLX plays an important role in PD
pathology. Expression of a constitutively active mutant of NCLX, which
enhances Ca2+ export from mitochondria has been shown to be neu-
roprotective in both PINK1 and LRRK2 PD model [4,91]. An interesting
study from Hail et al. [92] showed that inhibition of VDAC1 oligo-
merization with AKOS-022 inhibits neuronal cell death and therefore
might have an important impact on neuronal death in PD. Thus, all
these studies support the view that the proper homeostasis of mi-
tochondrial Ca2+ is crucial for well-being of the DNs. If so, anti-PD
treatments should take into account the compounds that prevent mi-
tochondrial Ca2+ overload.
What could be the drug for treating Ca2+ dependent mitochondrial
malfunctions in PD? Below we propose some requirements for such a
wonder drug and describe potential lead candidates. First, it should be
specific to mitochondrial Ca2+ route, either by blocking influx of Ca2+
or enhancing its efflux. Second, it should be crossing blood-brain bar-
rier and affecting preferentially dopaminergic neurons. Third, it cannot
affect muscles and other neurons to avoid significant side effects. Its use
will be recommended continuously since the early stages of the disease,
like for instance, hypertension drugs.
To get the better picture of mechanisms responsible for Ca2+
transport in mitochondria, we gathered them in Table 1 and assigned to
them known particles, that could be used as regulators, activators and
inhibitors. Most of influx mechanism toward mitochondrial matrix can
be blocked by Ruthenium Red or a couple of other chemicals. However,
until now no therapies connected with these were introduced, mostly
because of limited selectivity and efficacy. Yet, we think that pursuing
this way is really worth, because, as it was mentioned above, geneti-
cally blocking Ca2+ overload in mitochondria via Mcu had the rescue
effect in animal PD model. Alongside, chemical blocking of cell mem-
brane L-type channels by Isradipine is very promising. Still these
blockers are widely used to induce and stimulate controlled Ca2+
dysregulation in most of calcium field research. Recently a specific
mPTP inhibitor – AntiOxBEN3 was developed, which may open a way
to consecutive approach of chemical model of Ca2+ overload in the cell
[93]. There are still some unknown fields for activators/inducers of
mechanisms responsible for Ca2+ efflux from mitochondria. Would an
induction of more efficient Ca2+ export be an effective counterbalance
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to overload causing pathologies? Another option is to focus on the
regulation mechanism of MCU, residing outside mitochondria – inside
the MAMs and ER. These parts of the cell could be more specifically
targeted and then it would influence the MCU efficiency.
4. Concluding remarks
Parkinson’s disease is a neurodegenerative disorder, the actual
cause of which remains unknown. However, growing understanding
about mechanisms leading to PD phenotype have been accumulated
which includes progressive loss of dopaminergic (DA) neurons in the
substantia nigra pars compacta. The mechanisms behind the selective
loss of DA neurons in the SNpc of PD patients is under active in-
vestigation. Nevertheless, studies using animal and cellular models
based on familial form of PD or environmental factors (e.g. MPTP
toxicity) is providing useful insights into the mechanisms of neurode-
generation of DA neurons. Importantly, changes in mitochondrial Ca2+
homeostasis are one of the prominent markers for the neuronal loss in
PD pathology. Mitochondrial Ca2+ aids the bioenergetic status of the
cell and thus fine tuning of the mitochondrial Ca2+ is essential for a
cell. Malfunctioning of the mitochondrial Ca2+ transporters leading to
Ca2+ overload causes mitochondrial membrane potential collapse,
disintegration of mitochondria, release of pro apoptotic proteins and
ultimately cell death. Therefore, targeting mitochondrial Ca2+ sensors
and/or transporters represents an attractive therapeutic strategy in PD.
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